Cytori Therapeutics De: (NASD: CYTX)
$2.51
-0.03 (-1.18%)
Volume 180,428
May 22 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 2.50 - 2.60 |
| 52wk Low - High | 2.04 - 4.93 |
| Previous Close | 2.54 |
| Avg. Volume | 229,350 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 170.62 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.90 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.43 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 2 |
Zacks Recommendation
|
Outperform |
Zacks Industry Rank
|
96 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.43 |
| Current Quarter Estimate | -0.13 |
| Most Accurate Estimate | -0.13 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | -0.49 |
| Expected Earnings Growth | NA |
Company Description
Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.13 | -0.11 | -0.43 | -0.34 |
| Number of Estimates | 3 | 3 | 3 | 3 |
| Low Estimate | -0.13 | -0.12 | -0.47 | -0.41 |
| High Estimate | -0.12 | -0.10 | -0.40 | NA |
| Year Ago EPS | -0.12 | -0.17 | -0.55 | -0.43 |
| EPS Growth | -5.56% | 35.29% | 21.21% | 22.31% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CYTORI THERAPEU | CYTX | 2.54 | |
|
| AETERNA ZENTARS | AEZS | 2.08 | |
|
| ANIKA THERAPEUT | ANIK | 14.45 | |
|
| GENTIUM SPA-ADR | GENT | 8.90 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACHILLION PHARM | ACHN | 7.75 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.45 | |
|
| ALEXION PHARMA | ALXN | 102.67 | |
|
| ALKERMES INC | ALKS | 31.98 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Medivation Loss Narrower Than Expected
May 13, 2013
Osiris Loss In-Line with Expectations
May 08, 2013
Zacks Rank #1 Addition for Monday
Apr 22, 2013
Report for CYTX
May 13, 2013
Financials
| EPS TTM | -0.49 |
| Sales | 9 |
| Net Income | -31 |
| Price/Earnings | NA |
| Price/Book | 72.30 |
| Price/Cash Flow | NA |
| Price/Sales | 15.53 |
News
Position Yourself for Big Returns in the Stem Cell Space: Jason Kolbert - Kapitall
May 10, 2013
Safe Stem Cell Therapy for Healing Is Still a Strong Bet - TheMotleyFool
May 7, 2013
4 Health Care Stocks Under $10 to Watch - TheStreet.com
Apr 16, 2013
Benzinga`s Top Initiations - Benzinga
Mar 6, 2013
Benzinga`s Top Initiations - Benzinga
Feb 20, 2013
UPDATE: Acendiant Capital Initiates Cytori Therapeutics at Buy; Regenerative Medicine Pure Play - Benzinga
Feb 20, 2013
5 Stocks Setting Up to Break Out - TheStreet.com
Jan 25, 2013
CAPScall of the Week: Neuralstem - TheMotleyFool
Jan 2, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 2 |
| Average Target Price | 9.00 |
| Industry Rank by ABR | 96 out of 265 |
| Rank in Industry | 4 out of 157 |
